Moomoo AIのまとめ
Tharimmune, a clinical-stage biotechnology company, reported its financial performance and business developments for the quarter ended June 30, 2024. The company recorded a net loss of $2,325,057 for the quarter, with a net loss per share of $2.42. This compares to a net loss of $2,336,914 and a net loss per share of $52.06 for the same period in the previous year. The company's total operating expenses for the quarter were $2,373,454, which included research and development costs of $999,553 and general and administrative expenses of $1,373,901. Tharimmune's business development has been marked by the advancement of its therapeutic candidates, including TH104, which has shown positive results in a Phase 1 clinical trial. The company has also entered into significant agreements, such as the Avior License Agreement for the development of TH104 and TH103, and the Enkefalos License Agreement for global rights to cyclotides for delivering HER2 antibodies. Tharimmune's future plans include pursuing a 505(b)(2) approval pathway for TH104, initiating a Phase 2 trial for chronic pruritus in PBC patients, and advancing TH3215 and TH1940 into IND-enabling studies in 2025.
Tharimmune, a clinical-stage biotechnology company, reported its financial performance and business developments for the quarter ended June 30, 2024. The company recorded a net loss of $2,325,057 for the quarter, with a net loss per share of $2.42. This compares to a net loss of $2,336,914 and a net loss per share of $52.06 for the same period in the previous year. The company's total operating expenses for the quarter were $2,373,454, which included research and development costs of $999,553 and general and administrative expenses of $1,373,901. Tharimmune's business development has been marked by the advancement of its therapeutic candidates, including TH104, which has shown positive results in a Phase 1 clinical trial. The company has also entered into significant agreements, such as the Avior License Agreement for the development of TH104 and TH103, and the Enkefalos License Agreement for global rights to cyclotides for delivering HER2 antibodies. Tharimmune's future plans include pursuing a 505(b)(2) approval pathway for TH104, initiating a Phase 2 trial for chronic pruritus in PBC patients, and advancing TH3215 and TH1940 into IND-enabling studies in 2025.
クリニカルステージのバイオテクノロジー企業であるサーミュニーの2024年6月30日終了の四半期の財務パフォーマンスとビジネスの進展を発表しました。同社は四半期に2,325,057ドルの純損失を計上し、1株あたりの純損失は2.42ドルでした。これは、前年同期の2,336,914ドルの純損失および1株あたりの純損失52.06ドルに比べ、減少しています。同社の四半期の総営業費用は、1,373,901ドルの一般および管理費用を含む、999,553ドルの研究開発費用を含む2,373,454ドルでした。サーミュニーのビジネス開発は、第1相臨床試験で陽性結果を示したTH104などの治療候補の進展で注目されて...すべて展開
クリニカルステージのバイオテクノロジー企業であるサーミュニーの2024年6月30日終了の四半期の財務パフォーマンスとビジネスの進展を発表しました。同社は四半期に2,325,057ドルの純損失を計上し、1株あたりの純損失は2.42ドルでした。これは、前年同期の2,336,914ドルの純損失および1株あたりの純損失52.06ドルに比べ、減少しています。同社の四半期の総営業費用は、1,373,901ドルの一般および管理費用を含む、999,553ドルの研究開発費用を含む2,373,454ドルでした。サーミュニーのビジネス開発は、第1相臨床試験で陽性結果を示したTH104などの治療候補の進展で注目されています。同社はまた、TH104およびTH103の開発のためのAviorライセンス契約、HER2抗体の配信に関するサイクロチドのグローバルライツのためのEnkefalosライセンス契約など、重大な契約にも参入しています。サーミュニーの将来の計画には、TH104の505(b)(2)承認経路の追求、PBC患者の慢性かゆみの第2相試験の開始、TH3215とTH1940をIND有効化研究に進めることが含まれます。
役に立った
役に立たない
